Johnson &amp; Johnson (JNJ.US) announced on Friday that it has halted the mid-stage study of its experimental drug due to its failure to meet efficacy targets in a mid-term analysis for patients with moderate to severe atopic dermatitis (eczema).
The company stated that the drug JNJ-5939 is being tested in eczema patients, showing good tolerability, but did not meet the high efficacy standards required to advance development

Johnson & Johnson announced on Friday that it has halted the mid-stage study of its experimental drug due to its failure to meet efficacy targets in a mid-term analysis for patients with moderate to severe atopic dermatitis (eczema). The company stated that the drug JNJ-5939 is being tested in eczema patients, showing good tolerability, but did not meet the high efficacy standards required to advance development

Johnson & Johnson suspends mid-term trial of experimental eczema drug